New brain imaging study seeks to uncover early clues in Alzheimer's
NCT ID NCT07482072
First seen Mar 19, 2026 · Last updated Jun 18, 2026 · Updated 15 times
Summary
This study aims to better understand how blood flow and sugar use in the brain are altered in Alzheimer's disease, especially in people who also have type 2 diabetes. Researchers will use advanced PET scans to measure these changes in 60 participants across three groups: people with Alzheimer's, people with both Alzheimer's and diabetes, and healthy older adults. The goal is to identify early brain changes that could lead to earlier diagnosis and new treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Copenhagen University Hospital Herlev
RECRUITINGHerlev, 2730, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.